Cabaletta Bio, Inc.

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies targeting autoimmune diseases. The company's lead candidate, resecabtagene autoleucel, is a CD19-CAR T cell therapy incorporating a 4-1BB co-stimulatory domain currently in Phase 1/2 trials across multiple indications including dermatomyositis, lupus nephritis, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, and systemic sclerosis. The company also advances two earlier-stage programs: DSG3-CAART, a CAR T therapy in Phase 1 for mucosal pemphigus vulgaris, and MuSK-CAART, in Phase 1 development for MuSK antibody-positive myasthenia gravis.

Cabaletta maintains research collaborations with academic institutions including the University of Pennsylvania and Children's Hospital of Philadelphia, alongside partnerships with cell therapy manufacturers and developers such as Oxford Biomedica, Autolus Holdings, and WuXi Advanced Therapies. The company has also licensed intellectual property from Nanjing IASO Biotherapeutics for certain development programs.

Headquartered in Philadelphia, Pennsylvania, Cabaletta operates with approximately 148 full-time employees and maintains operations concentrated in the United States. The company was incorporated in 2017 and previously operated under the name Tycho Therapeutics before rebranding in August 2018.